eCite Digital Repository

COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development

Citation

Vogelmeier, CF and Fuhlbrigge, A and Jauhiainen, A and Scheepers, LEJM and Bengtsson, T and Peterson, S and Karlsson, N and Sethi, T and Locantore, N and Tal-Singer, R and Rennard, S and Fageras, M and Da Silva, CA, COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development, Respiratory Medicine, 173 pp. 1-16. ISSN 0954-6111 (2020) [Refereed Article]


Preview
PDF
Pending copyright assessment - Request a copy
5Mb
  

DOI: doi:10.1016/j.rmed.2020.106175

Abstract

Background: Frequency of moderate and severe chronic obstructive pulmonary disease exacerbations is an important endpoint in clinical trials, but makes them large and lengthy when powered to evaluate it. We aimed to develop a composite endpoint (COPDCompEx) that could predict treatment effect on exacerbations, enabling the design of shorter early phase clinical trials requiring fewer patients.

Methods: In this post hoc analysis, data from 20 randomized controlled trials were used to develop and test COPDCompEx. Diary events were tested against predefined threshold values for peak expiratory flow, reliever medication use, and symptoms. A COPDCompEx event was defined as first occurrence of a diary event, a moderate or severe exacerbation, or a study dropout. Ratios of event frequency, treatment effect and future trial sample size were compared between COPDCompEx and moderate and severe exacerbations.

Findings: At 3 months, the proportion of patients experiencing COPDCompEx events increased over 3-fold versus exacerbations alone. All components contributed to COPDCompEx event rate. Treatment effects at 3 months were closely matched between COPDCompEx and exacerbations, and the large net gain in power substantially reduced the required sample size.

Interpretation: may be used to predict treatment effect on moderate and severe exacerbations of chronic obstructive pulmonary disease. This may enable the design of shorter Phase 2 clinical trials requiring fewer patients when compared with current exacerbation studies, with exacerbations as a key Phase 3 endpoint. This would, therefore, allow more efficient decision-making with reduced burden and risk to study participants.

Item Details

Item Type:Refereed Article
Keywords:COPD, clinical trial endpoints, exacerbation, treatment effect, drug development
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Respiratory diseases
Objective Division:Health
Objective Group:Clinical health
Objective Field:Efficacy of medications
UTAS Author:Scheepers, LEJM (Dr Lieke Scheepers)
ID Code:142406
Year Published:2020
Deposited By:Menzies Institute for Medical Research
Deposited On:2021-01-14
Last Modified:2021-01-15
Downloads:0

Repository Staff Only: item control page